Immunohistochemistry for c-MET, HLA class II, and CD68 does not show prognostic value in early-stage classic Hodgkin lymphoma patients in the EORTC-GELA H9 intergroup randomised trial
Rodrigo Martinez Alcala, Lydia Visser, Catherine Fortpied, Christophe Fermé, Michel Henry-Amar, Berthe Aleman, Anne Arens, Sidsel Juul · 2026
Read Immunohistochemistry for c-MET, HLA class II, and CD68 does not show prognostic value in early-stage classic Hodgkin lymphoma patients in the EORTC-GELA H9 intergroup randomised trial by Rodrigo Martinez Alcala, Lydia Visser, Catherine Fortpied, Christophe Fermé, Michel Henry-Amar, Berthe Aleman, Anne Arens, Sidsel Juul (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0360080.txt.
Description
Rodrigo Martinez Alcala and seven colleagues published this research article in PLOS ONE in 2026. It concerns early-stage classic Hodgkin lymphoma, a cancer of the lymph system. The team tested whether staining tumor tissue for three markers, CD68, c-MET, and HLA class II, could help predict how patients would do.
The data come from the H9 trial run jointly by EORTC and GELA, a large randomised treatment study across several countries. As the title states, the marker tests did not show prognostic value in these patients. A clear negative answer like this still helps doctors, because it rules out tests that would add cost and effort without guiding care.
Catalog record
| CREATOR | Rodrigo Martinez Alcala, Lydia Visser, Catherine Fortpied, Christophe Fermé, Michel Henry-Amar, Berthe Aleman, Anne Arens, Sidsel Juul |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 29539 |
| LICENSE | CC_BY |
| RIGHTS | CC BY |
| SOURCE | PLOS |